Innoviva, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45781M1018
USD
20.80
-0.18 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Keros Therapeutics, Inc.
Ligand Pharmaceuticals, Inc.
Innoviva, Inc.
ImmunityBio, Inc.
Ardelyx, Inc.
MannKind Corp.
Revance Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Morphic Holding, Inc.
ACELYRIN, Inc.
EQRx, Inc.
Why is Innoviva, Inc. ?
1
High Management Efficiency with a high ROCE of 30.79%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.93 times
3
Poor long term growth as Operating profit has grown by an annual rate -9.22% of over the last 5 years
4
Positive results in Jun 25
  • OPERATING CASH FLOW(Y) Highest at USD 200.62 MM
  • DEBT-EQUITY RATIO (HY) Lowest at 2.74 %
  • INTEREST COVERAGE RATIO(Q) Highest at 1,260.69
5
With ROCE of 28.07%, it has a risky valuation with a 3.15 Enterprise value to Capital Employed
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 13.18%, its profits have risen by 73.3% ; the PEG ratio of the company is 0.2
6
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
  • Along with generating 13.18% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Innoviva, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Innoviva, Inc. for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Innoviva, Inc.
9.53%
1.39
26.09%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
4.16%
EBIT Growth (5y)
-9.22%
EBIT to Interest (avg)
12.42
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.31
Tax Ratio
28.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.79%
ROE (avg)
41.84%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.16
EV to EBIT
11.23
EV to EBITDA
9.21
EV to Capital Employed
3.15
EV to Sales
5.34
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
28.07%
ROE (Latest)
20.43%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 200.62 MM

DEBT-EQUITY RATIO (HY)

Lowest at 2.74 %

INTEREST COVERAGE RATIO(Q)

Highest at 1,260.69

CASH AND EQV(HY)

Highest at USD 944.61 MM

NET SALES(Q)

Highest at USD 103.74 MM

EPS(Q)

Highest at USD 0.77

0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Innoviva, Inc.
Operating Cash Flow
Highest at USD 200.62 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Interest Coverage Ratio
Highest at 1,260.69
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio
Lowest at 2.74 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales
Highest at USD 103.74 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

EPS
Highest at USD 0.77
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 944.61 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Depreciation
Highest at USD 10.04 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)